# A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)

> **NCT02461563** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 12 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** 200 mg MK-1075
- **DRUG:** 400 mg MK-1075
- **DRUG:** 800 mg MK-1075

## Key facts

- **NCT ID:** NCT02461563
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-23
- **Primary completion:** 2015-12-23
- **Final completion:** 2015-12-23
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02461563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02461563, "A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02461563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*